Bayer AG

Equities

BAYN

DE000BAY0017

Market Closed - Xetra Other stock markets 11:44:30 2025-07-11 am EDT			5-day change	1st Jan Change
27.34 ^EUR	-1.58%		+4.37%	+41.56%

Jul. 11	BAYER AG : Jefferies reiterates its Neutral rating	ZD
Jul. 11	Health Rounds: Experimental Bayer drug eases menopause-like symptoms from breast cancer therapy	RE

Bayer Aktiengesellschaft Presents at 2025 dbAccess Global Consumer Conference, Jun-05-2025 08:30 AM

Published on 06/05/2025 at 10:37, updated on 06/05/2025 at 11:38

Presenter Speech
Falko Friedrichs (Analysts)

Good morning, everyone. Thank you for attending so early in the morning. I hope you had a good first days at the conference here. It's my super big pleasure

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Bayer AG

BAYER AG : Jefferies reiterates its Neutral rating	Jul. 11	ZD
Health Rounds: Experimental Bayer drug eases menopause-like symptoms from breast cancer therapy	Jul. 11	RE
Bayer Receives U.K. Approval for Hot Flashes Treatment	Jul. 10	DJ
Bayer receives approval for Lynkuet(TM) (Elinzanetant) in UK	Jul. 10	RE
Bayer Rules Out Further Plant Closures in Germany After Frankfurt Exit	Jul. 10	RE
Reaches socially acceptable agreements for the withdrawal from Frankfurt/Main site and secures remaining company sites in Germany until 2030	Jul. 10	RE
Bayer Submits Gadoquatrane for EU Approval to Offer Lower-dose MRI Contrast Agent	Jul. 10	MT
Bayer: application for approval of its contrast agent	Jul. 10	CF
Bayer Seeks EU Approval for Low-Dose MRI Contrast Agent Gadoquatrane	Jul. 10	MT
Bayer files for EU approval of gadoquatrane	Jul. 10	RE
Bayer Wins Maiden Approval For Menopausal Hot Flashes Medication From UK Regulator	Jul. 09	MT
German Equities Jump Amid EU-US Trade Deal Optimism	Jul. 08	MT
MHRA approves elinzanetant to treat moderate to severe vasomotor symptoms caused by menopause	Jul. 08	RE
UK Clears Bayer Medicine for Menopause-related Hot Flashes	Jul. 08	MT
Bayer Treats First Patient in Early-stage Trial for Retinal Disorder Drug Candidate	Jul. 08	MT
Bayer Ag and BlueRock Therapeutics LP Announces First Patient Receives Investigational Therapy in Phase 1/2a Clinical Trial of OpCT-001 for the Treatment of Primary Photoreceptor Diseases	Jul. 08	CI
Bayer: testing OpCT-001, an experimental cell therapy	Jul. 08	CF
Vincerx Pharma, Inc. and Vnrx, Inc Announces Termination of License Agreement with Bayer Aktiengesellschaft and Bayer Intellectual Property Gmbh	Jul. 07	CI
BAYER AG : JP Morgan gives a Neutral rating	Jul. 07	ZD
BAYER AG : Goldman Sachs keeps its Buy rating	Jul. 04	ZD
General Mills changing Nature Valley labels after lawsuit's herbicide claim	Jul. 01	RE
Bayer Announces Executive Changes for North America	Jul. 01	CI
BAYER AG : UBS reaffirms its Neutral rating	Jul. 01	ZD
BAYER AG : JP Morgan reiterates its Neutral rating	Jun. 30	ZD
European shares see monthly declines as markets eye trade developments	Jun. 30	RE